Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine with R-GDP in Refractory or Relapsed NHL
NCT03535753Phase 1Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of decitabine in non-Hodgkin lymphoma (NHL), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
decitabine
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03535753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535753.